@article{b1f06588fc394745aa1a9bc8c942d786,
title = "Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T-cell responses in humans",
abstract = "Type 2 allergen-specific T cells are essential for the induction and maintenance of allergies to foods, and Tregs specific for these allergens are assumed to be involved in their resolution. However, it has not been convincingly demonstrated whether allergen-specific Treg responses are responsible for the generation of oral tolerance in humans. We observed that sustained food allergen exposure in the form of oral immunotherapy resulted in increased frequency of Tregs only in individuals with lasting clinical tolerance. We sought to identify regulatory components of the CD4+ T-cell response to food allergens by studying their functional activation over time in vitro and in vivo. Two subsets of Tregs expressing CD137 or CD25/OX40 were identified with a delayed kinetics of activation compared with clonally enriched pathogenic effector Th2 cells. Treg activation was dependent on IL-2 derived from effector T cells. In vivo exposure to peanut in the form of an oral food challenge of allergic subjects induced a delayed and persistent activation of Tregs after initiation of the allergen-specific Th2 response. The novel finding of our work is that a sustained wave of Treg activation is induced by the release of IL-2 from Th2 effector cells, with the implication that therapeutic administration of IL-2 could improve current OIT approaches.",
keywords = "IL-2, antigen-specific T cell, food allergy, oral tolerance, peanut, regulatory T cell",
author = "Daniel Lozano-Ojalvo and Tyler, {Scott R.} and Aranda, {Carlos J.} and Julie Wang and Scott Sicherer and Sampson, {Hugh A.} and Wood, {Robert A.} and Burks, {A. Wesley} and Jones, {Stacie M.} and Leung, {Donald Y.M.} and {de Lafaille}, {Maria Curotto} and Berin, {M. Cecilia}",
note = "Funding Information: J. Wang receives research support from National Institute of Allergy and Infectious Diseases, Aimmune, DBV Technologies, and Regeneron, and consultancy fees from ALK Abello and Jubilant HollisterStier. S. Sicherer reports royalty payments from UpToDate and from Johns Hopkins University Press; grants to his institution from the National Institute of Allergy and Infectious Diseases, from Food Allergy Research and Education, and from Pfizer; and personal fees from the American Academy of Allergy, Asthma and Immunology as Deputy Editor of the Journal of Allergy and Clinical Immunology: In Practice, outside of the submitted work. H.A. Sampson receives consultancy fees from N‐Fold, LLC, DBV Technologies, and Siolta Therapeutics, grant funding from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID), and royalties from Elsevier. R.A. Wood receives research support from NIH, Aimmune, DBV, Genentech, Novartis, Regeneron, and Siolta, and Royalties from UpToDate. S.M. Jones reports grants to her institution from the National Institute of Allergy and Infectious Diseases and from Food Allergy Research and Education; clinical trials funding to her institution from Aimmune Therapeutics, Inc., DBV Technologies, Inc., Regeneron Pharmaceuticals, Inc., Astellas Pharma, Inc., Genentech, Inc.; and personal fees from Aimmune Therapeutics, Inc. as a member of the scientific advisory board and FDA advisory consultant, from Regeneron Pharmaceuticals, Inc. as a research advisory consultant, and from Astellas Pharma, Inc. as scientific advisory consultant. D.Y.M. Leung receives research support from NIH and Sanofi‐Genzyme Pharma and acts as a Consultant/Advisory Board Member for Boeheringer Ingelheim, Evommune Inc., Genentech Inc., Leo Pharmaceuticals, and Incyte Corporation. M. Curotto de Lafaille received advisory fees from Genentech. The rest of the authors have nothing to disclose. Funding Information: This work was funded by NIAID R01 AI151707, U19 AI136053, R01 AI130343, and K99HG011270. D. Lozano‐Ojalvo and C. Aranda were funded in part by a postdoctoral fellowship from the Spanish Fundaci{\'o}n Alfonso Mart{\'i}n Escudero and Spanish Fundaci{\'o}n Ram{\'o}n Areces, respectively. Publisher Copyright: {\textcopyright} 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",
year = "2022",
doi = "10.1111/all.15512",
language = "English",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell Publishing Ltd",
}